Aerovate Therapeutics
Stock Forecast, Prediction & Price Target
Aerovate Therapeutics Financial Estimates
Aerovate Therapeutics Revenue Estimates
Aerovate Therapeutics EBITDA Estimates
Aerovate Therapeutics Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $8.14M Low: $8.14M High: $8.14M avg. 0% | Avg: $16.49M Low: $16.49M High: $16.49M avg. 102.47% | Avg: $75.61M Low: $75.61M High: $75.61M avg. 358.40% |
Net Income
% change YoY
| $-22.96M N/A | $-51.51M -124.32% | $-75.52M -46.61% | Avg: $-54.05M Low: $-89.00M High: $-4.21M avg. 28.43% | Avg: $-17.24M Low: $-21.06M High: $-6.84M avg. 68.08% | Avg: $-33.09M Low: $-33.09M High: $-33.09M avg. -91.86% | Avg: $-27.10M Low: $-27.10M High: $-27.10M avg. 18.10% |
EBITDA
% change YoY
| $-23.00M N/A | $-53.16M -131.09% | $-81.31M -52.93% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.94 N/A | -$2.1 -123.40% | -$2.87 -36.66% | Avg: -$1.51 Low: -$3.38 High: -$0.16 avg. 47.38% | Avg: -$0.55 Low: -$0.8 High: -$0.26 avg. 63.41% | Avg: -$1.26 Low: -$1.26 High: -$1.26 avg. -127.47% | Avg: -$1.03 Low: -$1.03 High: -$1.03 avg. 18.10% |
Operating Expenses
% change YoY
| $23.02M N/A | $53.23M 131.24% | $81.40M 52.91% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Aerovate Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 5.68% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -89.00M, average is -54.05M and high is -4.21M.
What is Aerovate Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 115.21% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Aerovate Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 0.35% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$3.38, average is -$1.51 and high is $-0.16.
What is the best performing analyst?
In the last twelve months analysts have been covering Aerovate Therapeutics stock. The most successful analyst is Eun Yang.